Teva and Apotex debut generic Gleevec drugs in the USA

6 August 2016

Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) revealed on Friday the launch of a generic equivalent to Gleevec(imatinib mesylate) tablets,100mg and 400mg, in the USA for multiple indications approved by the FDA.

Imatinib mesylate tablets had annual sales of approximately $2.42 billion in the USA, according to IMS data as of May 2016, quoted by Teva. Gleevec is marketed by Swiss pharma giant Novartis (NOVN: VX).

India’s Sun Pharma rolled out its copycat version of the blood cancer drug in February, and had six months market exclusivity, which has now expired. Gleevec was one of the drugs that pharmacy benefits manager CVD Health will remove from its listing, effective 2017, in favor of generics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK